De-intensification of treatment in human papilloma virus related oropharyngeal carcinoma: Patient choice still matters for de-escalation and for the COVID era.
作者信息
Iqbal Muhammad Shahid, Warner Laura, Paleri Vinidh, Kovarik Josef, Kelly Charles
机构信息
Department of Clinical Oncology, Northern Centre for Cancer Care, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE7 7DN, UK.
Department of Head and Neck Surgery, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE7 7DN, UK.
出版信息
Oral Oncol. 2020 Jun;105:104768. doi: 10.1016/j.oraloncology.2020.104768. Epub 2020 May 3.
Abstract
摘要
相似文献
1
De-intensification of treatment in human papilloma virus related oropharyngeal carcinoma: Patient choice still matters for de-escalation and for the COVID era.
Oral Oncol. 2020 Jun;105:104768. doi: 10.1016/j.oraloncology.2020.104768. Epub 2020 May 3.
2
A proposal for risk-based and strategy-adapted de-escalation in human papillomavirus-positive oropharyngeal squamous cell carcinoma.
Cancer. 2021 Dec 1;127(23):4330-4338. doi: 10.1002/cncr.33851. Epub 2021 Aug 11.
3
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus-Associated Oropharyngeal Cancer.
JAMA Oncol. 2022 Oct 1;8(10):1513. doi: 10.1001/jamaoncol.2022.3464.
4
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus-Associated Oropharyngeal Cancer.
JAMA Oncol. 2022 Oct 1;8(10):1512-1513. doi: 10.1001/jamaoncol.2022.3461.
5
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus-Associated Oropharyngeal Cancer.
JAMA Oncol. 2022 Oct 1;8(10):1511-1512. doi: 10.1001/jamaoncol.2022.3458.
6
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus-Associated Oropharyngeal Cancer-Reply.
JAMA Oncol. 2022 Oct 1;8(10):1513-1514. doi: 10.1001/jamaoncol.2022.3467.
7
[Recent update on human papillomavirus related oropharyngeal carcinoma].
Zhonghua Bing Li Xue Za Zhi. 2022 Jun 8;51(6):573-575. doi: 10.3760/cma.j.cn112151-20220106-00009.
8
COVID-19 and human papillomavirus: Paradoxical immunity.
J Cosmet Dermatol. 2021 Jul;20(7):2001-2003. doi: 10.1111/jocd.14022. Epub 2021 Mar 9.
9
Synchronous primary neoplasia in patients with p16 positive oropharyngeal carcinoma: Does the 2nd cancer really matters?
Oral Oncol. 2021 Apr;115:105113. doi: 10.1016/j.oraloncology.2020.105113. Epub 2020 Dec 13.
10
HPV-related oropharyngeal carcinoma de-escalation protocols.
Lancet Oncol. 2017 Jun;18(6):704-705. doi: 10.1016/S1470-2045(17)30250-4. Epub 2017 Apr 20.
引用本文的文献
1
Radiotherapy based management during Covid-19 pandemic - A systematic review of presented consensus and guidelines.
Crit Rev Oncol Hematol. 2021 Aug;164:103402. doi: 10.1016/j.critrevonc.2021.103402. Epub 2021 Jun 30.
本文引用的文献
1
Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement.
Int J Radiat Oncol Biol Phys. 2020 Jul 15;107(4):618-627. doi: 10.1016/j.ijrobp.2020.04.016. Epub 2020 Apr 14.
2
De-intensification of therapy in human papillomavirus associated oropharyngeal cancer: A systematic review of prospective trials.
Oral Oncol. 2020 Apr;103:104608. doi: 10.1016/j.oraloncology.2020.104608. Epub 2020 Mar 9.
3
Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer.
J Clin Oncol. 2020 Apr 1;38(10):1050-1058. doi: 10.1200/JCO.19.02444. Epub 2020 Feb 4.
4
Phase II Trial of De-Intensified Chemoradiotherapy for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.
J Clin Oncol. 2019 Oct 10;37(29):2661-2669. doi: 10.1200/JCO.19.01007. Epub 2019 Aug 14.
5
Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: The Quarterback trial.
Oral Oncol. 2019 Aug;95:170-177. doi: 10.1016/j.oraloncology.2019.06.021. Epub 2019 Jun 25.
6
Priorities, concerns, and regret among patients with head and neck cancer.
Cancer. 2019 Apr 15;125(8):1281-1289. doi: 10.1002/cncr.31920. Epub 2019 Jan 15.
7
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.
Ann Oncol. 2019 Feb 1;30(2):297-302. doi: 10.1093/annonc/mdy522.
8
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
Lancet. 2019 Jan 5;393(10166):40-50. doi: 10.1016/S0140-6736(18)32779-X. Epub 2018 Nov 15.
9
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.
Lancet. 2019 Jan 5;393(10166):51-60. doi: 10.1016/S0140-6736(18)32752-1. Epub 2018 Nov 15.
10
Smoking impact on HPV driven head and neck cancer's oncological outcomes?
Oral Oncol. 2018 Jul;82:131-137. doi: 10.1016/j.oraloncology.2018.05.007. Epub 2018 May 26.
Zotero 插件